UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000001288
Receipt number R000001570
Scientific Title Add-on effect of Montelukast therapy for uncontrollable asthma patients with inhaled corticosteroids : A open-label multicenter study
Date of disclosure of the study information 2008/10/01
Last modified on 2008/08/02 17:03:23

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Add-on effect of Montelukast therapy for uncontrollable asthma patients with inhaled corticosteroids : A open-label multicenter study

Acronym

Add-on effect of Montelukast therapy for uncontrollable asthma patients with inhaled corticosteroids

Scientific Title

Add-on effect of Montelukast therapy for uncontrollable asthma patients with inhaled corticosteroids : A open-label multicenter study

Scientific Title:Acronym

Add-on effect of Montelukast therapy for uncontrollable asthma patients with inhaled corticosteroids

Region

Japan


Condition

Condition

Asthma

Classification by specialty

Pneumology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To evaluate add-on effect of Montelukast therapy for respiratory function and airway inflammation for unstable asthma symptom despite with inhaled corticosteroids therapy.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Pragmatic

Developmental phase

Not applicable


Assessment

Primary outcomes

Exhaled breath condensate(IL-4, RANTES, IL-8, TNF-a, IP-10, TGF-b, H2O2, sICAM1, Leukotrienes, etc.)
Respiratory function (peak expiratory flow)

Key secondary outcomes

Asthma Control Test
Asthma Quality of Life Questionnaire
clinical and laboratory adverse experiences


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Active

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

Treatment for 8 weeks with montelukast 10 mg once daily

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

70 years-old >=

Gender

Male

Key inclusion criteria

1) Patients had the consent for the study
2) Patients have mild-to-moderate persistent asthma according to Japanese asthma guidelines in 2006
3) under 24 score of Asthma Control Test
4) Patients had used inhaled corticosteroids over 8 weeks.

Key exclusion criteria

1) Patients with a history of hypersensitivity to montelukast
2) Patients on continuous therapy with oral corticosteroids
3) In-patients for asthma within one month prior to entry the study
4) Patients with complications that could affect the evaluation of efficacy, such as bronchiectasis.
5) Pregnant women and women suspected of being pregnant, breast-feeding women
6) Patients who physician judged "not eligible"

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Ichiro Kawase

Organization

Osaka university Graduate school of medicine

Division name

Department of Respiratory Medicine, Allergy and Rheumatic Diseases

Zip code


Address

2-2 Yamadaoka, Suita city, Osaka, 565-0871, Japan

TEL


Email



Public contact

Name of contact person

1st name
Middle name
Last name Mitsuhiro Yoshida

Organization

Osaka university Graduate school of medicine

Division name

Department of Respiratory Medicine, Allergy and Rheumatic Diseases

Zip code


Address


TEL

06-6879-3831

Homepage URL


Email

hiroyoshida@imed3.med.osaka-u.ac.jp


Sponsor or person

Institute

Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka university Graduate school of medicine

Institute

Department

Personal name



Funding Source

Organization

Department of Respiratory Medicine, Allergy and Rheumatic Diseases, Osaka university Graduate school of medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2008 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Preinitiation

Date of protocol fixation

2008 Year 07 Month 31 Day

Date of IRB


Anticipated trial start date

2008 Year 08 Month 01 Day

Last follow-up date

2009 Year 12 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2008 Year 08 Month 02 Day

Last modified on

2008 Year 08 Month 02 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000001570


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name